

species election is now rendered moot. As a formal matter, and, if necessary, but with traverse, Applicants elect species SEQ ID NO: 3.

The new claims, which are modeled after the allowed claims in U.S. Serial No. 08/159,339, are fully supported by the present specification and in related application 08/344,824 which is incorporated by reference in the first paragraph on page 1 of the present application. The present application will be further amended as necessary to physically incorporate any essential material currently incorporated by reference that is required to support allowable claims of the present application.

Support for the terms defining the binding affinity of the referenced peptides is found, *e.g.*, on p. 49 lines 27-29 of U.S. Serial No. 08/344,824 application incorporated by reference.

Support for the cancer-associated antigens HER2/neu, p53, MAGE, and prostate antigen; and pathogenic agents HIV, HBV, HCV, and malaria is found, for example, on page 4, line 31 through page 5, line 2 and page 24, lines 7-10.


Support for the lengths of the epitope is found, for example, on page 3, lines 5-7.

#### CONCLUSION

In view of the foregoing, Applicants submit that all claims now pending in this Application are in condition for allowance.

If a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer  
Reg. No. P-44,879

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
JMLSf 1012565 v1